-- 40 patients at Shanghai General Hospital
-- Uniformly excellent, easy to interpret images
-- Outstanding target-to-background imaging
-- One minor transient adverse event unrelated to drug product
-- 5 additional compassionate-use patients in Germany
-- US IND for Phase 1 therapeutic study planned for 2022
Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce it has completed a Phase 1 study investigating the safety, dosimetry and efficacy of RAD201 in HER2 positive breast cancer subjects, in concert with its collaborators at Shanghai General Hospital in China and NanoMab in London, UK and Hong Kong, China.
The single domain antibody RAD201 is a novel single domain antibody, engineered to bind the imaging isotope Tc-99m which targets a protein called human epidermal growth factor receptor 2 (HER2) often associated with breast cancer. HER2 overexpression in breast cancer is often associated with aggressive disease and consequently, poor prognosis.
For more information, download the attached PDF.
Download this document
